Vol. 3 No. 4 (2023)
Reimbursement Reviews

Tebentafusp (Kimmtrak)

decorative image

Published April 21, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses tebentafusp (Kimmtrak), 100 mcg/0.5 mL, solution, IV infusion.
  • Indication: For the treatment of human leukocyte antigen (HLA)-A*02:01-positive adults with unresectable or metastatic uveal melanoma.